3 Multi-Specialty Hospital Network, Regional Hospital Group and Diagnostic Testing Network Stocks With a Strong Future Roadmap: Fortis Healthcare, Krishna Institute of Medical Sciences and Thyrocare Technologies

Hospital network and diagnostic testing stocks let investors follow companies that deliver treatment and the testing that guides it. Fortis Healthcare, Krishna Institute of Medical Sciences and Thyrocare Technologies cover a national multi-specialty hospital network, a regional hospital group and a high-volume diagnostic testing network.

This list covers three hospital network and diagnostic testing stocks with complete current figures: Fortis Healthcare, Krishna Institute of Medical Sciences and Thyrocare Technologies. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital Network and Diagnostic Testing Stocks?

Hospital network and diagnostic testing stocks are listed companies that run hospitals or laboratories at scale. Their earnings depend on bed capacity, occupancy, the mix of procedures and test volumes.

Hospital Network and Diagnostic Testing Stocks at a Glance

On valuation, Fortis Healthcare and Thyrocare Technologies trade at a P/E below the industry P/E, while Krishna Institute of Medical Sciences trades above it, which reflects the growth the market already expects. Readers comparing hospital network and diagnostic testing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital network and diagnostic testing stocks can use the coming numbers to test whether growth is holding.

Why Do Hospital Network and Diagnostic Testing Stocks Have a Strong Roadmap in India?

Hospital network and diagnostic testing stocks have a strong roadmap in India because rising insurance cover, growing health awareness and a shift towards organised providers are lifting demand for both treatment and testing.

• Insurance cover. More insured families choose organised hospitals for planned care.
• Regional depth. Hospital groups with a strong local base add beds in markets they know well.
• Testing volumes. A wide collection network lifts test volumes without heavy new spending.

Why Fortis Healthcare Features Among These Hospital Network and Diagnostic Testing Stocks

Among the hospital network and diagnostic testing stocks on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.

Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%.

In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6.

Roadmap: The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

What to watch: Track bed additions, occupancy and revenue per occupied bed.

Why Krishna Institute of Medical Sciences Features Among These Hospital Network and Diagnostic Testing Stocks

Among the regional hospital group shares on this list, Krishna Institute of Medical Sciences, known as KIMS Hospitals, runs a network of multi-specialty hospitals in Telangana, Andhra Pradesh and other states, with strengths in cardiac, neuro and transplant care.

In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%.

Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6.

Roadmap: The company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.

What to watch: Track bed additions, occupancy and revenue per occupied bed.

Why Thyrocare Technologies Features Among These Hospital Network and Diagnostic Testing Stocks

Among the three companies on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.

The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.

Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore.

Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.

Fortis Healthcare vs Krishna Institute of Medical Sciences vs Thyrocare Technologies on Key Financials

The table below sets the three hospital network and diagnostic testing stocks side by side on revenue, profit and margin, using reported figures.

Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Fortis Healthcare has the largest FY26 revenue at Rs 9,178 crore, and Krishna Institute of Medical Sciences shows the fastest revenue growth with a 23.8% compound annual rate. A useful habit with hospital network and diagnostic testing stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several diagnostic collection network stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Hospital Network and Diagnostic Testing Stocks

Every theme carries risks that deserve a check before any decision. For these hospital network and diagnostic testing stocks, the main points are: Long-term regional hospital group shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Ramp-up timing. New hospitals take time to reach stable utilisation.
• Doctor availability. Expert doctors are central to growth and hard to attract.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital network and diagnostic testing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital Network and Diagnostic Testing Stocks

Hospital network and diagnostic testing stocks reward investors who follow bed additions, occupancy and test volumes together. Fortis Healthcare, Krishna Institute of Medical Sciences and Thyrocare Technologies each have a clear path to wider reach. Based on the 22 October 2026 close, Fortis Healthcare trades at Rs 726.65, Krishna Institute of Medical Sciences at Rs 668.55 and Thyrocare Technologies at Rs 472.1. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these hospital network and diagnostic testing stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track hospital network and diagnostic testing stocks, set price alerts and get research-backed stock ideas.

What are hospital network and diagnostic testing stocks?

Ans. Hospital network and diagnostic testing stocks are listed companies that run hospitals or laboratories at scale. Their earnings depend on bed capacity, occupancy, the mix of procedures and test volumes. This list looks at three of them, Fortis Healthcare, Krishna Institute of Medical Sciences and Thyrocare Technologies, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.

Which hospital network and diagnostic testing stocks are covered in this list?

Ans. This list covers Fortis Healthcare, Krishna Institute of Medical Sciences and Thyrocare Technologies. Based on the 22 October 2026 close, Fortis Healthcare traded at Rs 726.65, Krishna Institute of Medical Sciences at Rs 668.55 and Thyrocare Technologies at Rs 472.1. Their return on equity ranges from 10.5% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 23.8%.

Why do hospital network and diagnostic testing stocks have a strong future roadmap in India?

Ans. Hospital network and diagnostic testing stocks have a strong roadmap in India because rising insurance cover, growing health awareness and a shift towards organised providers are lifting demand for both treatment and testing. The main drivers are as follows. Insurance cover. More insured families choose organised hospitals for planned care. Regional depth. Hospital groups with a strong local base add beds in markets they know well. Testing volumes. A wide collection network lifts test volumes without heavy new spending. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Fortis Healthcare performed financially?

Ans. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

How has Krishna Institute of Medical Sciences performed financially?

Ans. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.

How has Thyrocare Technologies performed financially?

Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

What risks should investors check before buying hospital network and diagnostic testing stocks?

Ans. Investors should check a few risks before buying hospital network and diagnostic testing stocks. Ramp-up timing. New hospitals take time to reach stable utilisation. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital network and diagnostic testing stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.